# Kymanox

Kymanox is an Asset Manager based in Morrisville, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Morrisville, United States
- **Region:** North America
- **Address:** Morrisville, NC, United States
- **Founded:** 2004
- **Assets under management:** Undisclosed
- **Website:** kymanox.com
- **LinkedIn:** https://www.linkedin.com/company/kymanox

## Regulatory record

- **Reports private funds:** No

## About

Stephen Perry launched Kymanox in 2004 after his own engineering and management tenure in the biopharma sector, positioning the firm as an outsourced extension of drug-development teams. The firm remains headquartered in Research Triangle Park, North Carolina. Wealth origin is tied to Perry's operational career rather than a single liquidity event. Kymanox deploys technical expertise across three core service lines: engineering, scientific, and regulatory consulting. The firm's footprint spans early-stage analytical development through commercial-scale aseptic processing. Confirmed engagements include working with sponsors on complex injectables, combination products, and novel drug-device platforms. Its geographic reach extends across North America and into European regulatory frameworks, supporting filings with both the FDA and EMA. Kymanox employs a workforce of over 190 professionals, distributed across U.S. offices and remote project sites. The firm has not disclosed capital deployment figures. Since 2022, Kymanox has been expanding its facility footprint — it opened a state-of-the-art laboratory and office space in Research Triangle Park to accommodate its growing project pipeline, 2022). Philanthropic structures or wealth-management vehicles operating alongside the core firm are not publicly documented. Kymanox differs structurally from traditional CROs by focusing exclusively on the late-stage development-to-commercialization handoff — the technical gap where most drug candidates fail. It does not conduct clinical trials, it does not hold intellectual property, and it does not take equity in client programs, preserving a conflict-free advisory posture unique among life-sciences service providers.

## Sectors

- Healthcare Services
- Pharmaceuticals & Biotechnology

## People

- Stephen M. Perry — Founder & CEO

## Questions

### Who runs investment and strategic decisions at Kymanox?

Stephen M. Perry founded Kymanox in 2004 and serves as its CEO. All strategic and operational decisions run through Perry's leadership team, with the firm operating as a privately held corporation without external private equity control disclosed.

### How does Kymanox source its client engagements?

Kymanox sources engagements through repeat relationships with venture-backed biotech firms and large-cap pharmaceutical companies. Its positioning as a transparent, IP-neutral technical partner often makes it a direct referral from venture capital and private equity investors needing clean-room advisory for portfolio companies approaching regulatory milestones.

### Does Kymanox take equity or royalties in client programs?

Kymanox does not publicly disclose taking equity or royalties in client programs. The firm's model is structured around fee-for-service technical consulting, a stance designed to avoid conflicts of interest when advising competing drug sponsors on regulatory and manufacturing strategy.

### What kinds of drug programs does Kymanox typically support?

Kymanox supports complex drug programs including sterile injectables, combination products, and novel drug-device platforms. The firm's expertise covers the technical gap between early-phase development and commercial-scale current good manufacturing practice (cGMP) production readiness.

### Which regions does Kymanox serve?

Kymanox primarily serves North American biopharma clients from its Research Triangle Park headquarters, with additional project work supporting European Medicines Agency (EMA) regulatory filings and ex-U.S. manufacturing site readiness for transatlantic sponsors.

## Related profiles

- [EcoSouth Services of Mobile](https://altss.com/profile/ecosouth-services-of-mobile)
- [Parallel Markets](https://altss.com/profile/parallel-markets-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/kymanox-corporation

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology